Selected research
Industry Research
Daptomycin API Industry Research Report 2026
Market perspective
The global Daptomycin API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Daptomycin API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Daptomycin API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Daptomycin API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Daptomycin API include Chongqing DaXin Pharmaceutical Co, Suzhou Pharmaceutical Technology Co, Livzon Group Fuzhou Fuxing Pharmaceutical Co, Huazhong Pharmaceutical Co, Xellia Pharmaceuticals, Tecoland Corporation, Rochem International Inc and Athos, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Daptomycin API market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Daptomycin API Market by Company
Chongqing DaXin Pharmaceutical Co
Suzhou Pharmaceutical Technology Co
Livzon Group Fuzhou Fuxing Pharmaceutical Co
Huazhong Pharmaceutical Co
Xellia Pharmaceuticals
Tecoland Corporation
Rochem International Inc
Athos
Daptomycin API Segment by Type
0.99
0.98
Others
Daptomycin API Segment by Application
350mg/vial
500mg/vial
Others
Daptomycin API Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daptomycin API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Daptomycin API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daptomycin API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Daptomycin API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Daptomycin API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Daptomycin API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 0.99
- 0.98
- Others
Applications
- 350mg/vial
- 500mg/vial
- Others
Companies covered
- Chongqing DaXin Pharmaceutical Co
- Suzhou Pharmaceutical Technology Co
- Livzon Group Fuzhou Fuxing Pharmaceutical Co
- Huazhong Pharmaceutical Co
- Xellia Pharmaceuticals
- Tecoland Corporation
- Rochem International Inc
- Athos
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Daptomycin API Market Size (2021-2032)
- 2.2.2 Global Daptomycin API Sales (2021-2032)
- 2.2.3 Global Daptomycin API Market Average Price (2021-2032)
- 2.3 Daptomycin API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 0.99
- 2.3.3 0.98
- 2.3.4 Others
- 2.4 Daptomycin API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 350mg/vial
- 2.4.3 500mg/vial
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Daptomycin API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Daptomycin API Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Daptomycin API Revenue of Manufacturers (2021-2026)
- 3.4 Global Daptomycin API Average Price by Manufacturers (2021-2026)
- 3.5 Global Daptomycin API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Daptomycin API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Daptomycin API, Product Type & Application
- 3.8 Global Manufacturers of Daptomycin API, Established Date
- 3.9 Global Daptomycin API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chongqing DaXin Pharmaceutical Co
- 4.1.1 Chongqing DaXin Pharmaceutical Co Company Information
- 4.1.2 Chongqing DaXin Pharmaceutical Co Business Overview
- 4.1.3 Chongqing DaXin Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chongqing DaXin Pharmaceutical Co Daptomycin API Product Portfolio
- 4.1.5 Chongqing DaXin Pharmaceutical Co Recent Developments
- 4.2 Suzhou Pharmaceutical Technology Co
- 4.2.1 Suzhou Pharmaceutical Technology Co Company Information
- 4.2.2 Suzhou Pharmaceutical Technology Co Business Overview
- 4.2.3 Suzhou Pharmaceutical Technology Co Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Suzhou Pharmaceutical Technology Co Daptomycin API Product Portfolio
- 4.2.5 Suzhou Pharmaceutical Technology Co Recent Developments
- 4.3 Livzon Group Fuzhou Fuxing Pharmaceutical Co
- 4.3.1 Livzon Group Fuzhou Fuxing Pharmaceutical Co Company Information
- 4.3.2 Livzon Group Fuzhou Fuxing Pharmaceutical Co Business Overview
- 4.3.3 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Livzon Group Fuzhou Fuxing Pharmaceutical Co Daptomycin API Product Portfolio
- 4.3.5 Livzon Group Fuzhou Fuxing Pharmaceutical Co Recent Developments
- 4.4 Huazhong Pharmaceutical Co
- 4.4.1 Huazhong Pharmaceutical Co Company Information
- 4.4.2 Huazhong Pharmaceutical Co Business Overview
- 4.4.3 Huazhong Pharmaceutical Co Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Huazhong Pharmaceutical Co Daptomycin API Product Portfolio
- 4.4.5 Huazhong Pharmaceutical Co Recent Developments
- 4.5 Xellia Pharmaceuticals
- 4.5.1 Xellia Pharmaceuticals Company Information
- 4.5.2 Xellia Pharmaceuticals Business Overview
- 4.5.3 Xellia Pharmaceuticals Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Xellia Pharmaceuticals Daptomycin API Product Portfolio
- 4.5.5 Xellia Pharmaceuticals Recent Developments
- 4.6 Tecoland Corporation
- 4.6.1 Tecoland Corporation Company Information
- 4.6.2 Tecoland Corporation Business Overview
- 4.6.3 Tecoland Corporation Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Tecoland Corporation Daptomycin API Product Portfolio
- 4.6.5 Tecoland Corporation Recent Developments
- 4.7 Rochem International Inc
- 4.7.1 Rochem International Inc Company Information
- 4.7.2 Rochem International Inc Business Overview
- 4.7.3 Rochem International Inc Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Rochem International Inc Daptomycin API Product Portfolio
- 4.7.5 Rochem International Inc Recent Developments
- 4.8 Athos
- 4.8.1 Athos Company Information
- 4.8.2 Athos Business Overview
- 4.8.3 Athos Daptomycin API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Athos Daptomycin API Product Portfolio
- 4.8.5 Athos Recent Developments
5 Global Daptomycin API Market Scenario by Region
- 5.1 Global Daptomycin API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Daptomycin API Sales by Region: 2021-2032
- 5.2.1 Global Daptomycin API Sales by Region: 2021-2026
- 5.2.2 Global Daptomycin API Sales by Region: 2027-2032
- 5.3 Global Daptomycin API Revenue by Region: 2021-2032
- 5.3.1 Global Daptomycin API Revenue by Region: 2021-2026
- 5.3.2 Global Daptomycin API Revenue by Region: 2027-2032
- 5.4 North America Daptomycin API Market Facts & Figures by Country
- 5.4.1 North America Daptomycin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Daptomycin API Sales by Country (2021-2032)
- 5.4.3 North America Daptomycin API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Daptomycin API Market Facts & Figures by Country
- 5.5.1 Europe Daptomycin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Daptomycin API Sales by Country (2021-2032)
- 5.5.3 Europe Daptomycin API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Daptomycin API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Daptomycin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Daptomycin API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Daptomycin API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Daptomycin API Market Facts & Figures by Country
- 5.7.1 South America Daptomycin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Daptomycin API Sales by Country (2021-2032)
- 5.7.3 South America Daptomycin API Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Daptomycin API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Daptomycin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Daptomycin API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Daptomycin API Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Daptomycin API Sales by Type (2021-2032)
- 6.1.1 Global Daptomycin API Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Daptomycin API Sales Market Share by Type (2021-2032)
- 6.2 Global Daptomycin API Revenue by Type (2021-2032)
- 6.2.1 Global Daptomycin API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Daptomycin API Revenue Market Share by Type (2021-2032)
- 6.3 Global Daptomycin API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Daptomycin API Sales by Application (2021-2032)
- 7.1.1 Global Daptomycin API Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Daptomycin API Sales Market Share by Application (2021-2032)
- 7.2 Global Daptomycin API Revenue by Application (2021-2032)
- 7.2.1 Global Daptomycin API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Daptomycin API Revenue Market Share by Application (2021-2032)
- 7.3 Global Daptomycin API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Daptomycin API Value Chain Analysis
- 8.1.1 Daptomycin API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Daptomycin API Production Mode & Process
- 8.2 Daptomycin API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Daptomycin API Distributors
- 8.2.3 Daptomycin API Customers
9 Global Daptomycin API Analyzing Market Dynamics
- 9.1 Daptomycin API Industry Trends
- 9.2 Daptomycin API Industry Drivers
- 9.3 Daptomycin API Industry Opportunities and Challenges
- 9.4 Daptomycin API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst